6 pharmaceutical companies are challenging on the exclusive sale rights for Ezetimibe
While domestic pharmaceutical companies in Korea are competing for the Rosuvastatin-Ezetimibe complex, competition for patent on the complex has opened up as well.
Especially, since the exclusive sale rights will be given on the developed products due to the patent linkage system that will be en...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
